Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Raftery

Showing results (1-10 of 159) with videos related to

Pageof 16
Sort By:
BMJ (Clinical Research Ed.)|March 29, 2003
Ethnic and sex bias in discretionary awardsJames Raftery
BMJ (Clinical Research Ed.)|January 15, 2009
NICE and the challenge of cancer drugsJames Raftery
The Health Service Journal|May 15, 2002
NHS activity. Running out of juiceJames Raftery
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|December 3, 2014
Health economic evaluation in EnglandJames Raftery
Clinical Advances in Hematology & Oncology : H&O|March 11, 2009
Regulation of drug pricing in australia, England, and new zealandJames Raftery
BMJ (Clinical Research Ed.)|January 28, 2009
Should NICE's threshold range for cost per QALY be raised? NoJames Raftery
BMJ (Clinical Research Ed.)|June 5, 2010
Multiple sclerosis risk sharing scheme: a costly failureJames Raftery
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
How should we value future health? Was NICE right to change?James Raftery
BMJ (Clinical Research Ed.)|October 15, 2013
Value based pricing: can it work?James Raftery
Methods in Molecular Biology (Clifton, N.J.)|June 11, 2008
Target selection: triage in the structural genomics battlefieldJames Raftery
Pageof 16

Showing results (1-10 of 159) with videos related to

Sort By:
Pageof 16
BMJ (Clinical Research Ed.)|March 29, 2003
Ethnic and sex bias in discretionary awardsJames Raftery
BMJ (Clinical Research Ed.)|January 15, 2009
NICE and the challenge of cancer drugsJames Raftery
The Health Service Journal|May 15, 2002
NHS activity. Running out of juiceJames Raftery
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|December 3, 2014
Health economic evaluation in EnglandJames Raftery
Clinical Advances in Hematology & Oncology : H&O|March 11, 2009
Regulation of drug pricing in australia, England, and new zealandJames Raftery
BMJ (Clinical Research Ed.)|January 28, 2009
Should NICE's threshold range for cost per QALY be raised? NoJames Raftery
BMJ (Clinical Research Ed.)|June 5, 2010
Multiple sclerosis risk sharing scheme: a costly failureJames Raftery
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
How should we value future health? Was NICE right to change?James Raftery
BMJ (Clinical Research Ed.)|October 15, 2013
Value based pricing: can it work?James Raftery
Methods in Molecular Biology (Clifton, N.J.)|June 11, 2008
Target selection: triage in the structural genomics battlefieldJames Raftery
Pageof 16